US Peptide Science Research Team
September 30, 2026
Tesofensine (formerly NS2330) represents a mechanistically distinct pharmacological approach to weight management compared to the GLP-1 agonists and dual agonists currently dominating obesity research. Developed by the Danish biotechnology company NeuroSearch in the late 1990s as a centrally acting monoamine reuptake inhibitor, tesofensine was initially evaluated for neurodegenerative indications before its weight-loss signal prompted redirection toward metabolic research. Understanding its mechanism, efficacy profile, and cardiovascular considerations is essential for researchers evaluating the broader anti-obesity research landscape.
Tesofensine functions as a small-molecule inhibitor of three presynaptic neurotransmitter transporters: the norepinephrine transporter (NET), serotonin transporter (SERT), and dopamine transporter (DAT). By blocking these transporters, tesofensine prevents the reuptake of noradrenaline, dopamine, and serotonin from the synaptic cleft, prolonging their dwell time and increasing extracellular monoamine concentrations in central nervous system regions governing appetite, reward, arousal, and autonomic tone.
In vitro potency measurements reveal a distinct pharmacological profile. According to revised binding data, tesofensine demonstrates the following inhibitory concentrations (IC50 values) en.wikipedia.org:
This pattern—highest selectivity for NET, intermediate for SERT, and lower for DAT—distinguishes tesofensine from earlier triple-action obesity compounds and from sibutramine, the withdrawn sympathomimetic amine that inhibited NET and SERT with weaker DAT activity.
The appetite-suppressant effect of tesofensine appears to be mediated principally through noradrenergic and dopaminergic pathways rather than serotonergic mechanisms. In preclinical studies using diet-induced obese rats, the hypophagic response was blocked by α1-adrenoceptor antagonists and dopamine D1 antagonists, but not by serotonergic antagonists, indicating that noradrenaline and dopamine carry the appetite-suppressing signal .
Research has further refined understanding of tesofensine's mechanism. A study examining the anorexigenic and cardiovascular effects of tesofensine in telemetrized conscious rats found that acute administration caused dose-dependent hypophagic effects as well as increased heart rate and blood pressure exa.ai. This mechanistic distinction is clinically relevant: the appetite-suppressant effect appears to operate through a brain-outward pathway focused on satiety signaling and feeding-circuit inhibition, rather than through peripheral metabolic augmentation as seen with GLP-1 receptor agonism.
The landmark efficacy study for tesofensine is the 2008 randomized, double-blind, placebo-controlled trial by Astrup and colleagues, published in The Lancet. This trial randomized 203 obese adults (BMI 30–40 kg/m²) across five Danish and European obesity centers to three tesofensine dose arms or placebo for 24 weeks alongside an energy-restricted diet en.wikipedia.org.
Primary outcomes after 24 weeks en.wikipedia.org:
When corrected for placebo and diet effects, the placebo-subtracted mean weight losses were reported as en.wikipedia.org:
The dose-response relationship was statistically significant. The most common adverse events were consistent with sympathomimetic and monoaminergic effects. At the time of publication, the weight loss achieved at the 0.5 mg dose was reported to be approximately double that produced by medications approved by the US Food and Drug Administration for obesity treatment as of 2008 en.wikipedia.org. However, this observation requires contextualization within the current GLP-1 and dual-agonist landscape.
Direct head-to-head trials comparing tesofensine to modern GLP-1 agonists or dual agonists have not been conducted. Cross-trial comparisons are inherently confounded by different trial durations, populations, and lifestyle interventions. Nevertheless, published data permit approximate positioning:
Tesofensine's weight-loss magnitude in Phase 2 trials is comparable to older-generation GLP-1 agonists but below that of semaglutide 2.4 mg and tirzepatide aminoscope.com. Its research niche derives from three factors: (1) oral small-molecule formulation, (2) mechanistically distinct central monoaminergic approach, and (3) emerging evaluation in indications where GLP-1 agonism has shown limited effect.
Tesofensine's sympathomimetic profile presents a key safety consideration. Increased heart rate and blood pressure at higher doses are mediated by norepinephrine transporter inhibition, which augments synaptic noradrenaline at cardiac and vascular adrenoceptors exa.ai.
A critical pharmacological insight emerged from preclinical rat studies: co-administration of metoprolol, a beta-1 selective adrenergic antagonist, prevented tesofensine-induced increases in heart rate and blood pressure while fully preserving the appetite-suppressing and weight-reducing effects exa.ai. This dissociation of cardiovascular from metabolic effects provided the scientific foundation for development of Tesomet, a fixed-dose combination of tesofensine with metoprolol.
Tesomet has been evaluated in orphan endocrine indications, including acquired hypothalamic obesity (following hypothalamic damage from craniopharyngioma surgery, radiotherapy, or other causes) and Prader-Willi syndrome, conditions in which GLP-1 agonist efficacy has been limited aminoscope.com. A small trial (n=21) in hypothalamic obesity reported approximately 6.3% additional weight loss over 24 weeks with Tesomet aminoscope.com.
Tesofensine has not received approval from the US Food and Drug Administration or European Medicines Agency. A Phase 3 registration trial was completed in Mexico by Saniona's commercial partner Medix in 372 adults with obesity, with both studied doses (0.25 mg and 0.5 mg) reported in 2018 to meet their primary and secondary weight-loss endpoints against placebo aminoscope.com. However, this trial was not published in a peer-reviewed journal. Mexico's regulator, Cofepris, issued a non-binding favorable opinion in 2023, but full marketing authorization has not been reported as of the most recent public updates aminoscope.com.
Tesofensine occupies a distinct position within the obesity research landscape. Unlike GLP-1 agonists and dual agonists, which work through incretin receptor signaling and act on the pancreas, GI tract, and central nervous system, tesofensine is a centrally acting small-molecule that raises monoamine tone to suppress appetite and increase satiety signaling. This mechanistic independence makes it a valuable comparator compound for understanding the relative contributions of different neurobiological pathways to weight regulation.
The oral bioavailability of tesofensine—a significant practical advantage over injectable peptide therapies—combined with its distinct mechanism and emerging evaluation in monogenic and acquired hypothalamic obesity syndromes, positions it as a complementary research agent within the current obesity pharmacology toolkit.
Future research directions include longer-duration trials to assess sustained efficacy and safety, investigation of tesofensine in monogenic obesity syndromes (Prader-Willi, POMC deficiency), and mechanistic studies examining potential interactions with other monoaminergic or metabolic interventions. The ongoing clinical development of Tesomet in hypothalamic obesity and Prader-Willi syndrome will provide important data on whether the cardiovascular safety profile achieved in preclinical models translates to clinical benefit in these specialized populations.